The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors.
 
David Levitz
No Relationships to Disclose
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - BMS; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Ira Winer
Consulting or Advisory Role - GOG Partners
Research Funding - Oncoceutics (Inst)
Travel, Accommodations, Expenses - Regeneron
 
Matthew Reilley
Consulting or Advisory Role - Pfizer; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Cardiff Oncology (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst); Takeda (Inst); Xencor (Inst); ZielBio (Inst)
 
Linda Duska
Consulting or Advisory Role - Ellipses Pharma (Inst); Inovio Pharmaceuticals; Merck (Inst); Regeneron
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Cerulean Pharma (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Millennium (Inst); Morab (Inst); Morphotek (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Syndax (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Editor, British Journal of Ob/Gyn; UpToDate
 
Vivek Subbiah
Consulting or Advisory Role - AADi; Abbvie (Inst); Bayer (Inst); Foundation Medicine; Illumina; Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Other Relationship - Clinical Care Options; Medscape
 
Debra Richardson
Honoraria - Zentalis
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; GlaxoSmithKline; Immunogen; Mersana; ProfoundBio
Research Funding - A2A Pharmaceuticals (Inst); aadi (Inst); Acrivon Therapeutics (Inst); Allorian (Inst); Aravive (Inst); Arch Oncology (Inst); ArQule (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); CanariaBio (Inst); Celsion (Inst); Clovis Oncology (Inst); Deciphera (Inst); DualityBio (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Immunogen/Abbvie (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nimbus Therapeutics (Inst); Nurix (Inst); OnCusp Therapeutics (Inst); Plexxikon (Inst); PMV Pharma (Inst); ProfoundBio (Inst); Scorpion Therapeutics (Inst); Shattuck Labs (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Valerion Therapeutics, LLC (Inst)
Travel, Accommodations, Expenses - Society of Gynecologic Oncology
 
Chet Bohac
Employment - Xencor
Stock and Other Ownership Interests - Amgen; Amgen; MacroGenics; MacroGenics; Xencor
 
Michael Chiarella
Employment - Xencor
Stock and Other Ownership Interests - Chimerix
 
Carlos Naranjo
Employment - MacroGenics; Xencor
Stock and Other Ownership Interests - Xencor
 
Jitendra Kanodia
Employment - Xencor Inc
Stock and Other Ownership Interests - Xencor
Travel, Accommodations, Expenses - Xencor Inc
 
Jacky Woo
Employment - Xencor
Stock and Other Ownership Interests - Xencor
Travel, Accommodations, Expenses - Xencor
 
Nicole Nevadunsky
Honoraria - Blueprint Medicines
Consulting or Advisory Role - LEK; LEK
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst); Tesaro (Inst)